Mavorixafor
Chronic Neutropenic Disorders
Phase 3Currently enrolling participants in pivotal, global Phase 3 trial (4WARD trial).
Key Facts
Indication
Chronic Neutropenic Disorders
Phase
Phase 3
Status
Currently enrolling participants in pivotal, global Phase 3 trial (4WARD trial).
Company
About X4 Pharmaceuticals
X4 Pharmaceuticals is a publicly traded biotech focused on rare immune disorders, leveraging its expertise in the CXCR4 pathway. The company achieved a major milestone with the 2024 FDA approval and U.S. launch of XOLREMDI® for WHIM syndrome, its first commercial product. X4 is now advancing mavorixafor into a pivotal Phase 3 trial for chronic neutropenia and has established commercialization partnerships in Europe and the Middle East, positioning itself as a commercial-stage rare disease company.
View full company profile